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Summary
Mutations in LRRK2 underlie an autosomal-dominant,
inherited form of Parkinson’s disease (PD) that mimics
the clinical features of the common ‘‘sporadic’’ form of
PD. The LRRK2 protein includes putative GTPase,
protein kinase, WD40 repeat, and leucine-rich repeat
(LRR) domains of unknown function. Here we show
that PD-associated LRRK2 mutations display disinhi-
bited kinase activity and induce a progressive reduc-
tion in neurite length and branching both in primary
neuronal cultures and in the intact rodent CNS. In con-
trast, LRRK2 deficiency leads to increased neurite
length and branching. Neurons that express PD-asso-
ciated LRRK2 mutations additionally harbor promi-
nent phospho-tau-positive inclusions with lysosomal
characteristics and ultimately undergo apoptosis.
Introduction
Parkinson’s disease is the second most common neuro-
degenerative disease, typically presenting as a progres-
sive movement disorder with slowness, rigidity, gait dif-
ficulty, and tremor at rest. The pathological hallmarks of
PD include the loss of dopamine (DA) neurons in the sub-
stantia nigra (SN) of the ventral midbrain and the pres-
ence of intracytoplasmic protein aggregates, termed
Lewy bodies (LB), composed of the synaptic vesicle-
associated protein a-synuclein (aSyn), ubiquitin, and
other components. An early feature of PD pathology is
the loss of dopaminergic axonal processes that extend
from the SN to the striatum, preceding the eventual
loss of DA neuron cell bodies (Abeliovich and Beal, 2006).
Recently, autosomal-dominant mutations in leucine-
rich repeat kinase-2 (LRRK2; also PARK8, dardarin,
OMIM 609007) were described in a familial Parkinsonism
syndrome that mimics the clinical and pathological fea-
tures of the common, sporadic form of PD (Paisan-Ruiz
et al., 2004; Zimprich et al., 2004). Pathological examina-
tion of patients with LRRK2 mutations has revealed do-
pamine (DA) neuron degeneration in the substantia nigra
(SN) of the ventral midbrain, as expected, but also sur-
prising heterogeneity regarding other pathological fea-
*Correspondence: aa900@columbia.edu
2 These authors contributed equally to this work.tures: some cases harbor aSyn-positive Lewy body
(LB) intracytoplasmic aggregates typical of sporadic
PD and other synucleinopathies; whereas other cases
either lack LB aggregates, display widespread LB pa-
thology in the cerebral cortex, or harbor tau-positive
axonal inclusions (Wszolek et al., 2004).
LRRK2 encodes a multidomain protein that includes
a Rho/Ras-like GTPase domain (termed Roc, for Ras in
complex proteins), a protein kinase domain related to
the mixed lineage kinase (MLK) family (Manning et al.,
2002), as well as WD40-repeat and LRR domains. An
additional domain C-terminal to the GTPase domain,
termed COR (for carboxy-terminal of Ras), is of un-
known function. PD-associated mutations in LRRK2 ap-
pear to fall throughout all of the identified structural seg-
ments. Interestingly, the G2019S and I2020T mutations
are both predicted to alter a highly conserved region
of the kinase domain termed the ‘‘activation loop,’’
based on structural homology to other protein kinases
(Davies et al., 2002).
Here we show that mammalian LRRK2 regulates neu-
rite maintenance and neuronal survival. Neurons that
express disease-associated mutant forms of LRRK2
display reduced neurite process length and complexity,
tau-positive inclusions with lysosomal features, and
ultimately apoptotic cell death. In contrast, neurons
deficient in LRRK2 harbor extended neuritic processes
with increased branching.
Results
LRRK2 Expression and Kinase Activity
To investigate the normal and pathological functions of
LRRK2, we generated plasmid vectors for overexpres-
sion of wild-type or disease-associated mutant alleles
of LRRK2 including G2019S, I2020T, Y1699C, and
R1441G (Figures 1A and 1B). A V5/His-epitope tag was
added to the amino terminus of each coding sequence
to distinguish the plasmid-encoded protein from endog-
enous LRRK2. Plasmids were transiently transfected
into COS7 cells, and cell lysates were analyzed by
SDS-PAGE and Western blotting with antibodies spe-
cific for the V5 epitope tag or LRRK2. A single 280 kDa
protein was observed in cytoplasmic lysates of cells
transfected with either wild-type or mutant LRRK2 plas-
mids, and transfection of LRRK2 plasmids led to a minor
increase in expression over the normal endogenous
level (less than 2-fold; Figure 1B and Figure S1A in the
Supplemental Data available online).
Lysates from transfected cells were immunoprecipi-
tated using an antibody for the V5 epitope tag, and sub-
sequently the immunoprecipitated complexes were as-
sayed for kinase activity toward purified myelin basic
protein (MBP) or myosin light chain (MLC), common
substrates for mixed-lineage kinase-related proteins.
Wild-type LRRK2 displayed a low level of kinase activity
in this assay, whereas the G2019S mutation led to signif-
icantly increased kinase activity toward both MBP and
MLC (Figure 1B and Figure S1B). These data are consis-
tent with the hypothesis that the G2019S mutation leads
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588Figure 1. LRRK2 Regulates Neurite Process Morphology
(A) Schematic of the primary structure of LRRK2, including the leucine-rich repeat (LRR), Roc, COR, protein kinase (PK), and WD-repeat domains.
Clinical mutations (in black) and the putative dominant-negative allele (in red) are shown.
(B) Upper panel displays an autoradiograph of the kinase assay with MBP substrate. Lower panel shows a Western blot for the V5 epitope tag,
demonstrating equal expression of the LRRK2 alleles. V5 epitope-tagged wild-type or mutant alleles of LRRK2 were overexpressed in COS7
cells. Cell lysates were immunoprecipitated with an antibody to the V5 epitope-tag, and protein kinase assays performed with myosin light chain
as a substrate.
(C) Knockdown of LRRK2with transfection of shRNA or vector control in transfected primary rat P1 cortical cultures. Immunocytochemical anal-
ysis was performed with a polyclonal antibody to LRRK2. LRRK2 protein is found throughout the cytoplasm and neurites and is enriched at the
cell cortex and at membrane structures. LRRK2 shRNA vector transfected cells display reduced LRRK2 staining relative to untransfected cells in
the same culture. Insets are magnified (2.53) views of the transfected soma.
(D) Camera lucida drawings of LRRK2-transfected cortical neurons. Wild-type, G2019S, I2020T, R1441G, Y1699C, or K1906M LRRK2 alleles
were transfected into cortical cultures at day 7 in vitro (7 DIV). At 2 weeks after transfection, cultures were imaged by confocal microscopy,
and process length was quantified by an observer blind to the identity of the allele. Process complexity and length was reduced significantly
in the G2019S and I2020T cultures relative to control vector or wild-type (wt) LRRK2, whereas the putative dominant-negative allele, K1906M,
leads to an increase in process length. Knockdown of LRRK2 with an shRNA vector leads to increased process length relative to shRNA vector
control.
(E) Quantification of soma diameter (lower panel) and total neurite process length (upper panel) as in (D). *p < 0.05. n = 55 cells in nine experiments
for G2019S and wt LRRK2 vectors; n = 85 cells in 13 experiments for control vector; n = 25 in five experiments for LRRK2 shRNA; n = 20 cells in
three experiments for K1906M and I2020T LRRK2; n = 15 cells in three experiments for all other sets.to disinhibited kinase activity relative to wild-type
LRRK2 (Gloeckner et al., 2005; West et al., 2005).
Additionally, two short hairpin RNA (shRNA)-based
plasmid vectors were generated to inhibit the expres-
sion of endogenous rodent LRRK2 by RNA interference
(RNAi; see Experimental Procedures). Transfection of ei-
ther of these plasmids into primary rat cortical cultures
or rat C6 glioma cells led to a reduction in the level of
LRRK2 mRNA and protein to less than 20% of baseline
levels, as determined by real-time quantitative rtPCR,
Western blotting, and immunocytochemistry with poly-
clonal antibodies for LRRK2 (Figure 1C and Figures
S1C and S1D). Immunocytochemical analysis of primary
cortical cultures further revealed the presence of LRRK2
throughout the soma and neurite processes of neurons
(Figure 1C). Immunocytochemistry with antibodies for
the polyhistidine epitope tag or for LRRK2 indicated
that plasmid-encoded wild-type and G2019S mutantLRRK2 localized similarly to the endogenous protein
(Figure S2). The G2019S LRRK2 mutant protein was
also present in distinctive spheroid-like inclusions within
cellular processes and at intracellular membranous
structures (see below).
LRRK2 Regulates Neuronal Process Morphology
Primary cortical cultures were transfected with plas-
mid vectors encoding wild-type or mutant forms of V5
epitope-tagged LRRK2 (or vector control), along with
enhanced green fluorescent protein (eGFP) sequences
to allow for the identification of transfected cells (w5%
of neurons; data not shown).
Overexpression of either of two clinically associated
missense mutant forms of LRRK2 within the kinase do-
main, G2019S and I2020T, led to a dramatic reduction
in neurite length and branching evident with respect to
both the longest neuronal processes, corresponding to
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589Figure 2. LRRK2 G2019S Mutation Leads to a Progressive Neurite Loss and Decreased Survival
(A) Primary rat cortical P1 cultures were transfected with LRRK2 alleles at 7 DIV, as indicated, and process length and branching were quantified
over time subsequently. Overexpression of mutant, but not wt, LRRK2 leads to a progressive decrease in process length over a 15 day period. In
contrast, LRRK2 knockdown by shRNA leads to a significant progressive increase in neurite process length. *p < 0.05; n = 85 cells in 13 exper-
iments for control vector; n = 45 cells in six experiments for wt LRRK2 vector; n = 37 cells in six experiments for G2019S LRRK2 vector; n = 25 cells
in five experiments for LRRK2 shRNA; n = 20 cells in three experiments for I2020T LRRK2 vector.
(B and C) Overexpression of mutant LRRK2 alleles lead to a significant reduction in cell survival, as visualized by propidium iodide (PI) exclusion
and absence of nuclear condensation. In (C), time course analyses of neuronal survival and the accumulation of intracellular inclusions are pre-
sented. n = 55 cells in nine independent experiments for control vector, G2019S, and wt; n = 20 cells in three independent experiments for I2020T.
*p < 0.05.
(D) Rescue of the LRRK2 shRNA knockdown requires only the kinase domain of the protein. Primary neuronal cultures were cotransfected with
LRRK2 shRNA along with full-length (FL) cDNA, a GTPase/Cor/kinase fragment (deleted in amino- and carboxy-terminal domains), or the kinase
domain alone. n = 31 cells in three experiments for shRNA+ wt FL LRRK2; n = 15 cells in three independent experiments for all other groups.
(E) Deletion analyses of LRRK2G2019S and wt alleles demonstrate a role for the kinase domain in the reduced neurite process length phenotype.
The G2019S kinase domain alone is sufficient to reduce process length and leads to a more dramatic phenotype than the full-length protein or
a truncated protein that harbors GTPase, COR, and kinase domains. The wt GTPase domain alone displays no activity. n = 15 cells in three
independent experiments for each group.axons, as well as total neurite outgrowth (Figures 1D and
1E and Figure S2C). This was confirmed by antibody
staining for axonal and dendritic markers (Figure S3A).
Neuronal polarity, as quantified by the ratio of axons to
dendrites, appeared unaltered. Overexpression of a Par-
kinsonism-associated missense mutation in the ROC
domain, R1441G, also led to a significant decrease in
process length, whereas a mutation within the COR do-
main, Y1699C, induced a relatively modest decrease in
process length that did not reach statistical significance
(Figures 1D and 1E). Overexpression of wild-type LRRK2
did not alter neuronal morphology, and the soma size of
neurons transfected with either wild-type (wt) or mutant
LRRK2 allele cDNA appeared similar to vector control.
As Parkinsonism-associated LRRK2 alleles display
disinhibited kinase activity and short processes, we hy-
pothesized that neurons deficient in LRRK2 activity may
demonstrate extended processes. First, we generated
an additional mutant form of LRRK2, K1906M, that is
predicted to lie within the ATP-binding segment of the
kinase domain (Cobb and Goldsmith, 1995) and has
been shown to generate a dominant-negative allele
(Cobb and Goldsmith, 1995; Gloeckner et al., 2005).
Overexpression of the K1906M allele led to a significantincrease in total process length, an effect that was par-
ticularly evident with respect to the length of the longest
process (Figures 1D and 1E). In a second approach,
LRRK2 accumulation was inhibited by RNAi. Cortical
neurons transfected with either of two shRNA vectors
specific for LRRK2 displayed a prominent increase in
neurite length (Figures 1D and 1E and data not shown).
LRRK2 Mutations and the Maintenance
of Neuronal Processes
To distinguish between a role in the generation and the
maintenance of process length, we performed a time
course analysis of neuronal morphology in cortical cul-
tures transfected with LRRK2 wild-type, G2019S, or
I2020T vectors, or with the LRRK2 knockdown shRNA
vector. Individual cells were followed by fluorescence
microscopy at 6, 9, 12, and 15 days subsequent to
transfection. This time course analysis demonstrated
that overexpression of PD-associated LRRK2 mutants
G2019S or I2020T, but not wild-type LRRK2, led to a pro-
gressive decline in the length and branching of neurite
processes (Figure 2A and Figure S3B). In contrast,
soma diameter was not significantly reduced in the mu-
tant LRRK2 transfected neurons. Time course analysis
Neuron
590Figure 3. tau-Positive Spheroidal Inclusions in Neurons that Overexpress Mutant G2019S LRRK2
(A) Confocal microscopy for GFP marker or immunohistochemistry for the His-tag epitope on LRRK2 G2019S demonstrate the presence of
spheroid inclusions within processes of all transfected cells (identical results were obtained with the I2020T mutation; data not shown).
LRRK2 protein does not appear to be enriched in the inclusions relative to the GFP marker. The inclusions additionally stain with antibodies
for tau phosphorylated at serine-202 (P-tau). Arrows point to inclusions.
(B) Quantification of aggregates as in (A). Inclusions are infrequent with wt LRRK2 overexpression or vector alone. Aggregates are significantly
more abundant in cells expressing mutant LRRK2 than in cells expressing wt LRRK2 or vector alone (p < 0.006). wt LRRK2 expression does lead
to an increase in aggregate formation relative to vector alone (p < 0.05; n = 85 cells in 13 experiments for control vector; n = 45 cells in six
experiments for wt LRRK2; n = 37 cells in six experiments for G2019S LRRK2; n = 20 cells in three experiments for I2020T.
(C and D) Ultrastructural analysis of primary cortical neurons expressing LRRK2 G2019S mutant allele or control vector by electron microscopy.
LRRK2-expressing cells harbor abundant electrondense structures that are suggestive of swollen lysosomes (arrow), as well as multivesicular
bodies (asterisk) and distended mitochondria associated with vacuoles (arrowhead). These are absent from control vector transfected cells (data
not shown). At highest magnification (D), membranes appear to surround the inclusions.
(E) Primary rat cortical cultures overexpressing the G2019S LRRK2 allele were immunostained with an antibody to LAMP1, a membrane marker
for acidic organelles including lysosomes and late endosomes. Staining is apparent at neurite inclusions (arrow) and colocalizes with LRRK2.of LRRK2 shRNA-mediated knockdown in cortical
neuron cultures indicated a gradual and progressive
increase in neurite process length (Figure 2A).
At late time points, decreased neuron survival was ev-
ident in neurons that express the Parkinsonism-associ-
ated LRRK2 mutant alleles. By day 15 posttransfection,
survival was significantly reduced in mutant LRRK2
transfected cortical neurons in comparison to wild-
type or vector-only transfected cells, as determined by
exclusion of propidium iodide staining and lack of nu-
clear condensation (45% survival in the G2019S versus
90% in the wild-type or vector transfected cells; p <
0.05; Figures 2B and 2C). Immunocytochemistry for ac-
tivated caspase-3 demonstrated that the mutant LRRK2
G2019S-transfected cells undergo an apoptotic mecha-
nism of cell death (Figure S3C).
Structure/Function Analysis of LRRK2 Reveals
a Critical Role for the Kinase Domain
To establish a structure/function relationship of LRRK2
domains, we sought to ‘‘rescue’’ the shRNA knockdown
allele phenotype by overexpression of LRRK2 cDNA
sequences. Transfection of the LRRK2 shRNA vector
along with overexpression of wild-type LRRK2 se-
quences effectively rescues the elongated process mor-
phology phenotype (Figure 2D and Figure S3D). Interest-
ingly, the kinase domain alone is sufficient for functional
rescue of the knockdown shRNA phenotype. Deletion
analysis revealed that the kinase domain alone is alsosufficient for the shortened neurite phenotype in the
context of Parkinsonism-associated LRRK2 G2019S
allele expression (Figure 2E). Finally, analysis of the phe-
notype of primary midbrain cultures showed that LRRK2
expression similarly regulates neurite process morphol-
ogy in dopamine neurons (Figure S4).
LRRK2 Mutations Induce tau-Positive Spheroid
Axonal Inclusions In Vitro
Prominent spheroid-like aggregates were observed
within the neuronal processes in all of the G2019S (37
out of 37) and I2020T (20 out of 20) transfected cortical
neurons, but only rarely in vector alone (3 out of 85) or
wild-type LRRK2 (4 out of 45) transfected cells, as deter-
mined by fluorescence microscopy for the eGFP marker
(Figures 3A and 3B). The inclusions stained positively
with a monoclonal antibody for the His epitope-tagged
G2019S LRRK2 protein. tau protein phosphorylated at
serine 202 (phospho-tau), visualized by immunostaining
with a phospho-specific antibody, appeared to accumu-
late specifically in the spheroidal inclusions, but these
structures did not stain positively with an antibody for
aSyn (Figure 3A and Figure S5).
Ultrastructural analyses by electron microscopy re-
vealed that neurons expressing the LRRK2 G2019S
mutant allele, but not control vector, display abnormal
accumulation of abundant electrodense structures
suggestive of swollen lysosomes (Figures 3C and 3D).
Additionally, multivesicular bodies (MVBs), distended
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591Figure 4. Overexpression of LRRK2 G2019S Kinase Domain Leads to Phospho-tau-Positive Inclusions, Increased Apoptosis, and Altered Pro-
cess Morphology in Rat Nigral Dopamine Neurons
(A) Adult rats were transduced unilaterally into the substantia nigra with AAV2 vectors harboring the G2019S or wild-type LRRK2 kinase domain,
or empty vector, along with AAV2-GFP. Histological examination was performed at 1 month. G2019S or wild-type LRRK2 kinase domain trans-
duction leads to the appearance of inclusions enriched in phospho-tau (at serine 404) as well as structural defects within TH-positive axons.
Scale bar, 20 mm.
(B) Activated caspase-3 staining in the nucleus of TH-positive infected neurons (indicated by white arrows) was seen to increase in G2019S
LRRK2 kinase domain transduced cells. Similar levels of transduction were observed in the substantia nigra for all vectors (Figure S6B); Scale
bar, 100 mm in upper panels, 10 mm in lower panels. LRRK2 G2019S or wt kinase domain transduction leads to a significant accumulation of in-
clusions relative to control vector alone. Inclusions in the striatum (>5 mm in diameter) were quantified. LRRK2 G2019S kinase domain transduc-
tion also resulted in a significant increase in activated caspase-3 staining localized in the nucleus. n = 8 animals in each group. **p < 0.05.
(C) To examine the role of LRRK2 on brain development, cDNA for wt or mutant alleles of LRRK2, or LRRK2 shRNA, were introduced along with
a GFP reporter into neural progenitor cells in E16 rat neocortex by in utero electroporation or lentiviral transduction. GFP-positive cells were
examined by confocal microscopy 4 days later. Electroporation of G2019S or I2020T alleles of LRRK2 led to a significant reduction in longest
process length relative to wt LRRK2 or control vector plasmid. Branch point number was reduced with overexpression of either wt or mutant
LRRK2 alleles relative to the vector control. In contrast, knockdown of LRRK2 by shRNA lentiviral transduction resulted in a significant increase
in process branching relative to lentiviral vector control (which is not significantly different from the plasmid vector control; data not shown).
LRRK2 knockdown resulted in a small increase in the length of the longest process, but the effect was not significant (p = 0.104). Branch points
are indicated by white arrows. Scale bar, 20 mm. n > 25 cells in >3 independent experiments for each group.
(D) Quantification of neuron process length and branching; *p < 0.05; **p < 0.005.mitochondria associated with vacuoles, and disrupted
cytoskeletal structures are observed. Consistent with
these findings, immunohistochemical analysis and con-
focal microscopy of neurons expressing the G2019S
LRRK2 allele revealed prominent membranous struc-
tures that stain with antibodies for the lysosomal
markers LAMP1 (Figure 4E) and cathepsin D (data not
shown). A time course analysis revealed that the inclu-
sions appear by day 6 posttransfection, coincident
with the neurite process phenotype (Figure S3D).
LRRK2 Mutation in Adult Nigral Dopamine Neurons
We further analyzed LRRK2 function in adult rat sub-
stantia nigra dopamine neurons (DNs) using an adeno-
associated virus-2 (AAV-2)-mediated gene transduction
model. As the kinase domain of LRRK2 is sufficient to
induce the G2019S-associated cellular phenotypes
in vitro (Figure 2D), and because of the genome size lim-
itation of viral vectors, we overexpressed the kinase do-
main alone of either wild-type or G2019S mutant LRRK2.
AAV-2 vectors were stereotactically injected into thesubstantia nigra pars compacta within the ventral mid-
brain of young adult rats along with GFP vector to allow
visualization of transduced cells. After 1 month, rats
were sacrificed, and histological examination of the
brain was performed. All analyses were performed by
an observer blinded to the animal genotype. In the con-
text of G2019S overexpression, and with wild-type
LRRK2 overexpression to a lesser extent, dopaminergic
axonal processes extending into the striatum displayed
prominent abnormal morphology and inclusions (as
identified by GFP expression and TH immunostaining;
Figures 4A and 4B, n = 8 for each group), consistent
with the in vitro phenotype. Immunohistochemical anal-
ysis revealed that the inclusions stained positively for
phospho-tau (at serine 404) but not for aSyn (Figure 4A
and Figure S6). Dopamine neurons in the substantia ni-
gra appeared grossly normal in the context of G2019S
LRRK2 expression, but apoptosis was significantly
increased, as quantified by nuclear morphology and
immunohistochemistry for activated caspase-3 (Figures
4A and 4B and Figure S6). Overexpression of the
Neuron
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some axonal inclusions, but to a lesser extent than the
G2019S mutant.
LRRK2 Regulates Neurite Process
Morphology in the CNS
Axonal processes appeared to be reduced in complex-
ity in the context of G2019S expression relative to vec-
tor control in the adult rat gene transduction model
(Figure S6C), but this was difficult to quantify due to
the high density of neuronal processes in the intact
CNS. To circumvent this, we used a technique that al-
lows for the marking of individual genetically altered
neurons within an otherwise normal CNS environment:
in utero intracerebral gene transduction of rat embryos
by vector injection into the lateral ventricles. Genetic
manipulation of neuronal progenitors within the periven-
tricular cell layer of E16 rat embryos can be achieved by
either plasmid vector electroporation or lentiviral trans-
duction (Tsai et al., 2005). After a 5 day period in utero,
the embryos (E21) are sacrificed, and brain sections
are visualized by confocal fluorescence microscopy.
Electroporation of vector alone labels neuronal cells
throughout layers 1 and 2 of the cerebral cortex that
appear morphologically as neurons and are immuno-
stained with a neuronal marker, Tuj1 (Figure S6D). Over-
expression of PD-associated mutant LRRK2 alleles,
G2019S or I2020T, dramatically reduced both the length
and the branching of neuronal processes, relative to
control vector (Figures 4C and 4D), consistent with the
phenotype observed in neuronal primary cultures. In
contrast, cortical neurons transduced with LRRK2
shRNA display a significant increase in the number of
branch points relative to control vector-transduced cells
(Figures 4C and 4D). Also, total axon length appeared to
be increased in the knockdown cells, although this did
not reach statistical significance. In summary, LRRK2
appears to regulate neuronal process morphology in
the intact CNS, consistent with the primary culture
analysis.
Discussion
A common feature of neurodegenerative disorders of
aging is the loss of neuronal processes early in the dis-
ease course. In Parkinson’s disease, loss of dopaminer-
gic axons and terminals that project from the SN to the
striatum precedes mDN cell death. Our data suggest
a role for LRRK2 in the maintenance of neuronal process
length and complexity in the mammalian brain. Autoso-
mal-dominant mutations in LRRK2 lead to disinhibited
kinase activity, a reduction in neuron process length
and complexity, and the accumulation of tau-positive
inclusions with lysosomal characteristics. Ultimately,
neurons that overexpress mutant alleles of LRRK2 un-
dergo apoptosis. Suppression of LRRK2 with shRNAs
or a dominant inhibitory allele leads to an opposite
phenotype of increased neurite process length and
complexity.
A prominent early feature of LRRK2 disease-associ-
ated mutant neurons is the presence of inclusions that
stain for phospho-tau and display abnormal lysosomal
features. It is possible that the observed inclusions are
not causally linked to the altered neurite process pheno-type, as the role of inclusions in neurodegenerative dis-
orders remains unresolved. However, we hypothesize
that pathological lysosome inclusions may represent
a proximal event in LRRK2 G2019S action given the ob-
served time course of their appearance and the pres-
ence of LRRK2 in these inclusions. A lysosomal nidus
of function would offer a potential cellular mechanism
for the altered neurite morphology, as prior studies
have shown that lysosomal regulatory proteins, such
as VAMP7 and synaptotagmin VII, play parallel regula-
tory roles in neurite morphology (Arantes and Andrews,
2006; Martinez-Arca et al., 2001). Additional investiga-
tions are necessary to determine the relationship of in-
clusions with respect to the altered neurite morphology
phenotype.
A hypothetical molecular target for LRRK2 kinase ac-
tivity would be tau, as the two proteins colocalize in in-
clusions. Of note, tau protein is also implicated in the
regulation of neurite process morphology as well as in
neurodegeneration. However, we have thus far failed
to detect evidence of direct phosphorylation of tau by
LRRK2 in vitro (data not shown). We favor a model in
which LRRK2 indirectly modifies tau through modula-
tion of the activity of other kinases previously implicated
in tau phosphorylation, such as GSK3b. Additional stud-
ies will be necessary to pinpoint the action of LRRK2 in
these signaling cascades.
LRRK2 G2019S overexpression in rodent adult dopa-
mine neurons leads to loss of nigrostriatal processes,
tau-positive inclusions, and apoptosis and is thus a use-
ful animal model for early LRRK2-associated disease.
Additional studies in nonhuman primates are now feasi-
ble using the AAV-2-based vectors we describe. These
cellular and animal models may promote the discovery
of effective therapeutics for LRRK2-associated disease.
Experimental Procedures
Vectors and In Vitro Assays
LRRK2 cDNA constructs were generated that harbor mouse LRRK2
sequences at the 50 terminus (NM_025730; bp 1–3738 of the coding
sequence) and human LRRK2 sequences downstream (AY_792511;
bp 3734–7584 of the coding sequence) and therefore would not be
subject to shRNA silencing by a rodent-specific vector. The knock-
down shRNA vector targets a region of the rodent LRRK2 gene
(NM_025730; bases 4789–4809) that is conserved in rodents but
divergent in human LRRK2 cDNA. G2019S, I2020T, K1906M,
Y1699C, and R1441G LRRK2 were generated by PCR-mediated
mutagenesis.
Immunoprecipitation and Western blot analysis were performed
essentially as described (Staropoli et al., 2003).
For analysis of LRRK2 kinase activity toward myelin basic protein,
immunoprecipitated immune complexes were incubated in kinase
buffer (30 mM Tris [pH 7.5], 20 mM MgCl2, 2 mM MnCl2) in the pres-
ence of 10 mM [g-32P]ATP, 10 mM cold ATP, and 1 mg myelin basic
protein or myosin light chain protein (Sigma). Phosphorylated myelin
basic protein was detected by SDS-PAGE and autoradiography.
Cell Culture and CNS Transduction Assays
Sprague-Dawley P1 rat primary dissociated cortical cultures were
prepared and transfected essentially as described in Xia et al.
(1996) with modified culture media explained below. Immunofluo-
rescence and microscopy were performed as described (Martinat
et al., 2006). The following antibodies and dilutions in staining solu-
tion (1% NDS, 0.1% Triton X-100 in PBS) were then used for primary
immunostaining: mouse anti-phospho-tau AT8 clone (Fitzgerald
Industries), 1:100; mouse anti-tau1 (Chemicon MAB361), 1:200;
rabbit anti-cleaved caspase 3 (Cell Signaling), 1:500; mouse
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1:500. Primary staining incubation times were 2 hr for phospho-tau
and His staining, and otherwise overnight. LAMP1 rabbit polyclonal
antibody (GeneTex), 1:100; LRRK2 rabbit polyclonal antibody
(Chemicon), 1:200; mouse monoclonal anti tau-1 (Chemicon),
1:100; rabbit a-P-tau (Santa Cruz; 1:200); rabbit polyclonal anti tau
phosphoserine-404 (Santa Cruz), 1:200; rabbit polyclonal anti-
VMAT2 (Chemicon), 1:200; sheep a-TH (Pelfreeze; 1:500); rabbit
polyclonal anti- cleaved caspase-3 (Cell Signaling), 1:250. Lyso-
Tracker Red DND-99 and MitoTracker Red CMXRos (Invitrogen)
were used in culture medium at concentrations of 100 nM and
500 nM, respectively, for live imaging of cells on a Zeiss LSM510
Meta Confocal Microscope. Electron microscopy was performed
as in Troy et al. (1992). Images were analyzed using Image-Pro
Plus (Mediacybernetics) software version 5.1.0.20. Statistical analy-
sis was performed using Statview software version 5.0. p values
were obtained using Fisher’s post hoc ANOVA.
In utero gene transduction was performed essentially as in Tsai
et al. (2005), and AAV-2-mediated transduction into the adult rat
SN essentially as in Kirik et al. (2002). Details of the stereotactic
injection procedures are described in Supplemental Experimental
Procedures.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/52/4/587/DC1/.
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